The Scale Report
AIHardwareStartupsFundingSportsCulturePolicyAI & Media List
Funding

Pilgrim Secures $25 Million Seed Round for Defense Biotech

Redwood City based Pilgrim Labs pulls in a $150 million valuation from prominent tech investors to develop advanced national security tools.

Sarah Kim 路 Sep 27, 2026 路 3 min read

Share饾晱PostLinkedInWhatsApp

Key highlights 路 3 min read

  • Pilgrim has successfully closed a $25 million seed funding round, pushing the Redwood City based biotechnology firm to a valuation of $150 million.
  • The funding round was led by Buckley Ventures.
  • The Scale Report understands that the influx of capital will allow Pilgrim to accelerate the development of its specialized defense biotechnology.
Pilgrim Secures $25 Million Seed Round for Defense BiotechThe Scale Report
Illustration based on @tradedvc on Instagram

Pilgrim has successfully closed a $25 million seed funding round, pushing the Redwood City based biotechnology firm to a valuation of $150 million. The company, which is focused on creating advanced biological solutions for national security and defense applications, is spearheaded by founder Jake Adler.

A Diverse Investor Base

The funding round was led by Buckley Ventures. The cap table includes a notable cohort of technology leaders and venture firms, including Brian Armstrong, Fred Ehrsam, Karim Atiyeh, Bryan Johnson, Paul Sciarra, and Peter Thiel. Additional participation came from Dylan Field, Charlie Songhurst, Cory Levy, Logan Graham, Sholto Douglas, The Chainsmokers, Conviction, and Cantos.

The Strategic Defense Pivot

The Scale Report understands that the influx of capital will allow Pilgrim to accelerate the development of its specialized defense biotechnology. As government interest in dual use technologies intensifies, this investment underscores a broader trend of Silicon Valley capital flowing into the modernization of national security infrastructure.

Historically, defense tech has struggled to attract venture interest due to long sales cycles and regulatory hurdles. However, the success of companies like Pilgrim suggests that elite investors are increasingly comfortable backing startups that blend high end biotech research with public sector contracting, signaling a shift in how early stage capital evaluates long term hardware and scientific risk.

PilgrimJake AdlerBuckley VenturesDefense TechBiotechVenture Capital

Reporting based on coverage from @tradedvc on Instagram.

The daily brief

The biggest stories in AI, venture, sports business and culture - once a day.

One short email from The Scale Report. No spam, unsubscribe any time.

Read next

TypeSafe AI Hits $7.5 Billion Valuation for Jev ModelThe Scale Report
Funding

TypeSafe AI Hits $7.5 Billion Valuation for Jev Model

By Sarah Kim 路 Oct 10, 2026 路 3 min read

Nous Research secures 1.5 billion valuation for agentic growthThe Scale Report
Funding

Nous Research secures 1.5 billion valuation for agentic growth

By Sarah Kim 路 Oct 8, 2026 路 3 min read

Lambda Seeks $4B Funding Round Before Planned 2027 IPOThe Scale Report
Funding

Lambda Seeks $4B Funding Round Before Planned 2027 IPO

By Sarah Kim 路 Oct 7, 2026 路 3 min read

Melius Raises $20M Series A After Pivoting Away From Ad SpendThe Scale Report
Funding

Melius Raises $20M Series A After Pivoting Away From Ad Spend

By Sarah Kim 路 Oct 7, 2026 路 3 min read

The daily brief

The biggest stories in AI, venture, sports business and culture - once a day.

One short email from The Scale Report. No spam, unsubscribe any time.

The Scale Report

Independent reporting on scale - AI, venture, hardware, sports business and culture.

AI & Media ListAboutContactPrivacy PolicyTerms of Service

Registration on or use of this site constitutes acceptance of our Terms of Service and Privacy Policy.

漏 2026 The Scale Report. All rights reserved.